Company intelligence / Profile preview
Medicines360
- Ownership
- Private
- Employees
- ~17
- Development stage
- Other
Overview
Medicines360 has successfully developed and commercialized Liletta®—a levonorgestrel-releasing intrauterine device—for contraception. The product underwent the largest and most diverse Phase 3 clinical study on a hormonal IUD in the US. Liletta® received FDA approval and has been made available through partnerships to increase access for underserved women. Avibela™, a branded version of the same device, is distributed internationally at affordable prices via subsidiary Impact RH360. The company continues to expand its portfolio with new contraceptive options such as an over-the-counter progestin-only pill currently under development.
- Therapeutic areas
- Women's Health
- Modalities
- DeviceHormone delivery systemSmall molecule
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Medicines360.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medicines360.